---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic burden and healthcare resource utilization. Topics: Annual healthcare costs and resource use in a commercially insured US population, research paid by Genentech; Uncontrolled CSU, resource use, and costs in US HealthVerity claims; Systemic corticosteroid use, adverse events, and resource use in US HealthVerity claims, Novartis-funded; Annual direct and indirect costs in 50 adults at allergy and dermatology clinics; 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Annual healthcare costs and resource use in a commercially insured US population, research paid by Genentech

> “The prevalence of chronic idiopathic or spontaneous urticaria is 0.11 % in a commercially insured US population.”
> “Oral corticosteroids were the most commonly prescribed medication, used in 54.7 % of patients. Patients accumulated a mean of 15.1 office visits per year (standard deviation 12.6). The mean all-cause healthcare cost totaled over US$9000 per year.”
> “Mean all-cause healthcare costs were US$9142 (SD US$21,835, median US$3659) (Fig. 1).”
> “Mean urticaria-related costs were US$997 (SD US$2322, median US$612).”
> “M.S. Broder and E. Chang are employed by Partnership for Health Analytic Research, LLC, a health services research company paid by Genentech, Inc. to conduct this research.”

Source: [Broder et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4529877/)

<a id="topic-2.2.1.8.2-2"></a>

### Uncontrolled CSU, resource use, and costs in US HealthVerity claims

> “Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.”
> “Overall, 200,298 patients were followed-up for a median of 2.3 years after diagnosis.”
> “Corticosteroids were the most prescribed treatment during follow-up among the 166,195 patients prescribed at least 1 treatment (94.3%). Proxy events were observed in 59.1% of the patients. HCRU and health care costs increased from baseline in patients with uncontrolled CSU during follow-up.”
> “Of patients with CSU who were prescribed treatment, more than 50% experienced uncontrolled CSU, which was associated with increased HCRU and health care costs.”

Source: [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/)

<a id="topic-2.2.1.8.2-3"></a>

### Systemic corticosteroid use, adverse events, and resource use in US HealthVerity claims, Novartis-funded

> “This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023).”
> “Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines.”
> “More frequent HCRU was generally observed after the first systemic corticosteroid prescription and with increasing duration of corticosteroid use.”
> “More frequent HCRU may also have additional implications for health care costs, which are not discussed here.”
> “This study and article publication, including the journal’s Rapid Service Fee, was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.”

Source: [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/)

<a id="topic-2.2.1.8.2-4"></a>

### Annual direct and indirect costs in 50 adults at allergy and dermatology clinics

> “The Johns Hopkins University allergy and dermatology ambulatory clinics.”
> “Fifty adults with active CIU were recruited in sequential order.”
> “Patients with CIU consumed a mean (SD) of $2047 ($1483) annually. Because CIU is primarily an outpatient disease, medication costs alone accounted for 62.5% ($1280) of the total annual cost. Indirect costs accounted for 15.7% ($322) of the total costs.”

Source: [DeLong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18209166/)

<a id="topic-2.2.1.8.2-5"></a>

### ASSURE-CSU: direct, indirect, and out-of-pocket costs by country and resource use

> “Total average (SD) annual direct costs per patient per year, as captured in the retrospective medical record review, ranged from PPP$907.1 ($2431.14) in Italy to PPP$2984.2 ($8969.46) in France. The major drivers of these costs were therapies (range, PPP$426.4‐$1788.7) and inpatient visits (range, PPP$250.7‐$1074.4) (Tables S5 and S6 in Appendix S5 and S6).”
> “Average indirect costs, or costs of patient‐reported total work productivity loss over 4 weeks, were driven primarily by the cost of presenteeism (range, PPP$544.5‐$1180.0); the mean (SD) cost of work productivity loss ranged from PPP$544.8 ($603.22) in France to PPP$1287.4 ($1123.80) in Germany (Table S7 in Appendix S7).”
> “Moreover, in ASSURE‐CSU, CSU‐related out‐of‐pocket expenses to patients averaged nearly PPP$500 per year and approached PPP$1000 in Canada.”
> “Among the 97 patients (14.4%) with at least one CSU‐related ED visit in the past 12 months, the annual mean (SD) number of visits was 1.8 (1.26). Hospitalization for CSU was recorded for 55 patients (8.2%), with a mean (SD) length of stay per hospitalization of 3.7 (2.67) days”

Source: [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)

<a id="topic-2.2.1.8.2-6"></a>

### Self-reported all-cause resource use over 6 months, 2019 National Health and Wellness Survey

> “Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).”
> “In terms of all-cause HCRU, 96.5% of the respondents had visited any healthcare provider in the past 6 months, and 60.2% reported visiting an emergency department a mean (SD) of 8.6 (11.9) and 3.7 (5.0) times, respectively. Meanwhile, 55.9% of respondents had been hospitalized in the past 6 months, with the mean (SD) number of hospitalizations being 4.4 (9.8).”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.8.2-7"></a>

### Review of the global burden of chronic urticaria: treatment and total cost ranges

> “Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society.”
> “Apart from treatment costs, with annual values between 900 and 2400 purchasing power parity dollars (PPP$) in Europe and the USA, CU is associated with a high consumption of medical resources and other indirect costs, which may reach a total annual cost of PPP$ 15 550.”

Source: [Gonçalo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32956489/)

<a id="topic-2.2.1.8.2-8"></a>

### Omalizumab spending in Oregon all-payer claims, all indications, 2024

> “Xolair (omalizumab) is an anti-immunoglobulin E (IgE) monoclonal antibody used to treat several allergic and inflammatory conditions, including moderate-to-severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.”
> “In the 2024 Oregon All Payer All Claims (APAC) data, 901 enrollees had 8,833 Xolair claims, with approximately $19.5 million in total gross payer spending.”
> “annual gross payer spending was approximately $21,618 per enrollee.”
> “APAC data showed approximately $1.8 million in total enrollee out-of-pocket spending, with an average annual cost of approximately $2,023 per enrollee and a median annual cost of $150.”

Source: [Oregon PDAB Xolair affordability review (2026)](https://dfr.oregon.gov/pdab/Documents/Xolair-2026.pdf)

<a id="topic-2.2.1.8.2-9"></a>

### Cost of routine laboratory screening in adults with CSU: US simulation

> “Average laboratory costs per simulated patient with CSU were $573 (standard deviation [SD], $41), with only 0.16% (SD, 3.99%) of tests resulting in improved clinical outcomes.”
> “From a simulated US population perspective, nation-wide screening costs could reach $941,750,741 to $1,833,501,483.”

Source: [Shaker et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31751758/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
